Misplaced Pages

Ferric derisomaltose, sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). It was approved for use in the United States in January 2020. It is given intravenously.

References

1. "Monofer iron (as ferric derisomaltose) 1000 mg/10 mL solution for injection vial (290834)". Therapeutic Goods Administration (TGA). 26 May 2022. Archived from the original on 14 April 2023. Retrieved 9 April 2023.
2. "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 31 March 2024. Retrieved 31 March 2024.
3. "Regulatory Decision Summary for Monoferric". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
4. ^ "Monoferric- ferric derisomaltose solution". DailyMed. 24 January 2020. Archived from the original on 1 October 2020. Retrieved 16 February 2020.
5. "Monoferric approval letter" (PDF). U.S. Food and Drug Administration (FDA). 16 January 2020. Archived (PDF) from the original on 17 February 2020. Retrieved 16 February 2020. This article incorporates text from this source, which is in the public domain.
6. "Drug Approval Package: Monoferric Injection". U.S. Food and Drug Administration (FDA). 7 May 2020. Archived from the original on 1 October 2020. Retrieved 13 August 2020.

• Medicine

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Drugs acting on the blood and blood forming organs
• Iron(III) compounds
• Blood and blood forming organ drug stubs